Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study-Reference-Cited by-同舟云学术

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study

Published:2020-09-28 Issue:1 Volume:23 Page:75-85
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Birkeland Kåre I.¹^ORCID,Bodegard Johan²^ORCID,Banerjee Amitava³⁴,Kim Dae Jung⁵^ORCID,Norhammar Anna⁶⁷,Eriksson Jan W.⁸^ORCID,Thuresson Marcus⁹,Okami Suguru¹⁰^ORCID,Ha Kyoung Hwa⁵,Kossack Nils¹¹,Mamza Jil Billy¹²,Zhang Ruiqi¹²,Yajima Toshitaka¹⁰,Komuro Issei¹³,Kadowaki Takashi¹⁴

Affiliation:

1. Oslo University Hospital and University of Oslo Oslo Norway

2. AstraZeneca Oslo Norway

3. Institute of Health Informatics University College London London UK

4. Department of Cardiology University College London Hospitals London UK

5. Department of Endocrinology and Metabolism Ajou University School of Medicine Suwon Republic of Korea

6. Cardiology Unit, Department of Medicine Karolinska Institute Solna Sweden

7. Capio S:t Görans Hospital Stockholm Sweden

8. Department of Medical Sciences, Clinical Diabetes and Metabolism Uppsala University Uppsala Sweden

9. Statisticon AB Uppsala Sweden

10. AstraZeneca Osaka Japan

11. Wissenschaftliches Institut für Gesundheitsökonomie und Gesundheitssystemforschung Leipzig Germany